These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1507659)

  • 1. Effects of pravastatin sodium alone and in combination with cholestyramine on hepatic, intestinal and adrenal low density lipoprotein receptors in homozygous Watanabe heritable hyperlipidemic rabbits.
    Kuroda M; Matsumoto A; Itakura H; Watanabe Y; Ito T; Shiomi M; Fukushige J; Nara F; Fukami M; Tsujita Y
    Jpn J Pharmacol; 1992 May; 59(1):65-70. PubMed ID: 1507659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits.
    Kurokawa J; Hayashi K; Toyota Y; Shingu T; Shiomi M; Kajiyama G
    Biochim Biophys Acta; 1995 Oct; 1259(1):99-104. PubMed ID: 7492622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (Pravastatin) and cholestyramine.
    Kume N; Kita T; Mikami A; Yokode M; Ishii K; Nagano Y; Kawai C
    Circulation; 1989 May; 79(5):1084-90. PubMed ID: 2496935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pravastatin on cholesterol metabolism in Watanabe heritable hyperlipidemic rabbits.
    Amorosa LF; Rozovski SJ; Ananthakrishnan R; Coly E; AlHinai A; Martucci C; Schneider SH; Shimamura T; Khachadurian AK
    Jpn Heart J; 1992 Jul; 33(4):451-63. PubMed ID: 1453550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pravastatin sodium, a competitive inhibitor of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases the cholesterol content of newly secreted very-low-density lipoprotein in Watanabe heritable hyperlipidemic rabbits.
    Shiomi M; Ito T
    Metabolism; 1994 May; 43(5):559-64. PubMed ID: 8177044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pravastatin on cholesterol metabolism of cholesterol-fed heterozygous WHHL rabbits.
    Harsch M; Gebhardt A; Reymann A; Lang G; Schliack M; Löser R; Braesen JH; Niendorf A
    Br J Pharmacol; 1998 May; 124(2):277-82. PubMed ID: 9641543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing hepatic cholesterol 7alpha-hydroxylase reduces plasma cholesterol concentrations in normocholesterolemic and hypercholesterolemic rabbits.
    Xu G; Salen G; Shefer S; Ness GC; Nguyen LB; Tint GS; Parker TS; Roberts J; Batta AK; Chen TS; Zhao Z; Kong X
    Hepatology; 1996 Oct; 24(4):882-7. PubMed ID: 8855192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase in hepatic low-density lipoprotein receptor activity during pregnancy in Watanabe heritable hyperlipidemic rabbits; an animal model for familial hypercholesterolemia.
    Shiomi M; Ito T; Watanabe Y
    Biochim Biophys Acta; 1987 Jan; 917(1):92-100. PubMed ID: 3790616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pravastatin decreases serum lipids and vascular cholesterol deposition in Watanabe heritable hyperlipidemic (WHHL) rabbits.
    Khachadurian AK; Shimamura T; Rozovski SJ; Ananthakrishnan R; Armenian B; Coly E; alHinai A; Martucci C; Schneider SH; Amorosa LF
    Jpn Heart J; 1991 Sep; 32(5):675-85. PubMed ID: 1774829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clearance of chylomicron-like lipid emulsions is increased in normal rabbits but not in heterozygous Watanabe heritable hyperlipidaemic rabbits following treatment with cholestyramine or pravastatin.
    Mamo JC; Bowler A; Redgrave TG; Elsegood CL
    Clin Exp Pharmacol Physiol; 1994 Sep; 21(9):687-94. PubMed ID: 7820948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unexpected inhibition of cholesterol 7 alpha-hydroxylase by cholesterol in New Zealand white and Watanabe heritable hyperlipidemic rabbits.
    Xu G; Salen G; Shefer S; Ness GC; Nguyen LB; Parker TS; Chen TS; Zhao Z; Donnelly TM; Tint GS
    J Clin Invest; 1995 Apr; 95(4):1497-504. PubMed ID: 7706454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pravastatin sodium, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases serum total cholesterol in Japanese White rabbits by two different mechanisms.
    Miyazaki A; Koga T
    Atherosclerosis; 2002 Jun; 162(2):299-306. PubMed ID: 11996949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of hepatic cholesterol metabolism in man.
    Angelin B
    Ann Med; 1991 Apr; 23(2):177-80. PubMed ID: 1906288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
    Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits.
    Suzuki H; Yamazaki H; Aoki T; Kojima J; Tamaki T; Sato F; Kitahara M; Saito Y
    Arzneimittelforschung; 2000 Nov; 50(11):995-1003. PubMed ID: 11187394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol synthesis in vivo and in vitro in the WHHL rabbit, an animal with defective low density lipoprotein receptors.
    Dietschy JM; Kita T; Suckling KE; Goldstein JL; Brown MS
    J Lipid Res; 1983 Apr; 24(4):469-80. PubMed ID: 6304219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of fluvastatin sodium on secretion of very low density lipoprotein and serum cholesterol levels. In vivo study using low density lipoprotein receptor deficient watanabe heritable hyperlipidemic rabbits.
    Shiomi M; Shiraishi M; Yata T; Ito T
    Arzneimittelforschung; 1994 Oct; 44(10):1154-6. PubMed ID: 7818592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low density lipoprotein receptor-independent hepatic uptake of a synthetic, cholesterol-scavenging lipoprotein: implications for the treatment of receptor-deficient atherosclerosis.
    Williams KJ; Vallabhajosula S; Rahman IU; Donnelly TM; Parker TS; Weinrauch M; Goldsmith SJ
    Proc Natl Acad Sci U S A; 1988 Jan; 85(1):242-6. PubMed ID: 3422421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mechanism of comparable serum cholesterol lowering effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A inhibitor, between once- and twice-daily treatment regimens in beagle dogs and rabbits.
    Fujioka T; Nara F; Shimada Y; Fukushige J; Shimotsu H; Shigehara E; Fukami M; Tsujita Y
    Jpn J Pharmacol; 1996 Apr; 70(4):329-35. PubMed ID: 8774761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired adrenal reserve in the Watanabe Heritable Hyperlipidemic rabbit: implications for LDL-receptor function in steroidogenesis.
    Hoeg JM; Loriaux L; Gregg RE; Green WR; Brewer HB
    Metabolism; 1985 Feb; 34(2):194-7. PubMed ID: 3969018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.